Trial reportEuropean journal of clinical nutrition2016
Antiobesity effect of Pediococcus pentosaceus LP28 on overweight subjects: a randomized, double-blind, placebo-controlled clinical trial.
Trial report in European journal of clinical nutrition, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 6 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Probiotics' effect on visceral and subcutaneous adipose tissue: a systematic review of randomized controlled trials.European journal of clinical nutrition · 2022Pooled it
- Effects of Probiotics and Synbiotics on Weight Loss in Subjects with Overweight or Obesity: A Systematic Review.Nutrients · 2021Pooled it
- Efficacy of Probiotics in Patients of Cardiovascular Disease Risk: a Systematic Review and Meta-analysis.Current hypertension reports · 2020Pooled it
- Fermented Dairy Products, Probiotic Supplementation, and Cardiometabolic Diseases: A Systematic Review and Meta-analysis.Advances in nutrition (Bethesda, Md.) · 2020Pooled it
- Pooled it
- Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.PloS one · 2018Pooled it
- Trial
- The Effect of theNutrients · 2024Trial
- Plant-DerivedNutrients · 2022Trial
- Plant-DerivedNutrients · 2021Trial
- Effect of probioticWorld journal of gastroenterology · 2021Trial
- Effects of Agave fructans (Agave tequilana Weber var. azul) on Body Fat and Serum Lipids in Obesity.Plant foods for human nutrition (Dordrecht, Netherlands) · 2018Trial
- Complete Genome Sequence Analysis, Probiotic Properties, and Safety Assessment of Healthy Human-Derived Pediococcus pentosaceus.Probiotics and antimicrobial proteins · 2026Article
- A 12-week randomized, double-blind, placebo-controlled exploratory pilot study of HFN2-008 (heat-treated Bifidobacterium longum HN001) for adiposity reduction in overweight adults.BMC nutrition · 2026Article
- Effects of probiotics and synbiotics on body weight management in individuals with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials.Physical activity and nutrition · 2026Article
- Alleviating Mechanism of Microencapsulated Compound Probiotics Against Obesity via PPAR Metabolic Pathway.Probiotics and antimicrobial proteins · 2026Article
- Postbiotics: emerging regulatory mechanisms and therapeutic applications in obesity and its complications.International journal of obesity (2005) · 2026Review
- Updated Insights into Probiotic Interventions for Metabolic Syndrome: Mechanisms and Evidence.Probiotics and antimicrobial proteins · 2026Review
- The therapeutic potential ofFrontiers in microbiology · 2026Review
- Incorporating Postbiotics into Intervention for Managing Obesity.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesThe population of the obese is increasing worldwide. Prevention and improvement of obesity are indispensable for decreasing the risk of metabolic disorders. We have recently shown that obesity and fatty liver are reduced by a plant-derived lactic acid bacterium, Pediococcus pentosaceus LP28 (LP28), in high-fat diet-induced obese mice. The aim of the present clinical study is to prove that LP28 is effective for reducing body fat and body weight, as shown in the experiment using mice. SUBJECTS/
methodsThe clinical trial was carried out as a double-blind, randomized, placebo-controlled study comprising 62 subjects (20-70 years of age, BMI 25-30 kg/m(2)). These subjects were randomly assigned to three groups that received living LP28, heat-killed LP28 or a placebo powder, administered orally once a day for 12 weeks.
resultsHeat-killed LP28 reduced BMI (0.45 kg/m(2), 95% CI (0.04, 0.86), P=0.035), body fat percentage (1.11%, (0.39, 1.82), P=0.002), body fat mass (1.17 kg (0.43, 1.92), P=0.004) and waist circumference (2.84 cm (0.74, 4.93), P=0.009) when compared with a placebo group. Fasting plasma glucose, HbA1c, fasting insulin, HOMA-IR and serum lipids levels did not change by either living LP28 or heat-killed LP28 intake.
conclusionsHeat-killed LP28 displays an antiobesity effect that reduces BMI, body fat and waist circumference, suggesting that the plant-derived lactic acid bacterium LP28 would be a promising preventive of metabolic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.